As we can see, mental health is gaining momentum during covid times and may remain the same even in post-covid era.
Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced it has raised $39 million in a Series B financing, led by Gilde Healthcare.
Big Health was founded by entrepreneur Peter Hames and Professor Colin A. Espie, the world sleep expert whose published research helped Peter overcome his insomnia. Their purpose is to help millions back to good mental health. Their “digital therapeutics” — Daylight™, for worry & anxiety, and Sleepio™, for poor sleep — are fully automated, scalable cognitive and behavioral programs. Big Health’s products are backed by 50 published clinical papers including 13 randomised controlled trials (RCTs), and are cited in leading clinical guidelines including the American College of Physicians and NICE. Today, millions of people worldwide have reimbursed access to Big Health’s products, via leading employers in the US and the UK’s NHS.
Read on
Big Health Raises $39 Million in Series B Financing from Gilde Healthcare, Morningside Ventures, Kaiser Permanente Ventures, and Octopus Ventures
San Francisco, CA (Thursday June 18, 2020) - Big Health, the global leader in digital therapeutics dedicated to helping millions back to good mental health, today announced it has raised $39 million in a Series B financing, led by Gilde Healthcare and joined by co-lead Morningside Ventures; existing investors Kaiser Permanente Ventures (KPV) and Octopus Ventures; and Samsung NEXT.
No comments:
Post a Comment